Propanc Biopharma (PPCB) Receivables - Other (2013 - 2016)

Propanc Biopharma (PPCB) posted quarterly Receivables - Other of $2300.0 for Q3 2016, up 3.6% quarter-over-quarter from $2220.0 in Q2 2016.

Propanc Biopharma (PPCB) Receivables - Other (2013 - 2016) Analysis & Trends

Propanc Biopharma (PPCB) has reported Receivables - Other for 2 consecutive years, with $2300.0 the latest figure, recorded in Q3 2016.

In Q3 2016, Receivables - Other changed N/A year-over-year to $2300.0; the TTM figure through Sep 2016 stood at $2300.0 (changed N/A YoY), while the FY2016 annual figure was $2220.0, changed N/A from the prior year.
Receivables - Other advanced to $2300.0 in Q3 2016 per PPCB's latest filing, from $2220.0 in the prior quarter.
Across five years, Receivables - Other topped out at $2300.0 in Q3 2016 and bottomed at -$130689.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Propanc Biopharma	587,855.41	587,855.41	-

Download Data